Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-ba6a3e01d1da47ecc915e34664ffddaf",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-ba6a3e01d1da47ecc915e34664ffddaf",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-ba6a3e01d1da47ecc915e34664ffddaf",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-ba6a3e01d1da47ecc915e34664ffddaf\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-ba6a3e01d1da47ecc915e34664ffddaf</b></p><a name=\"composition-en-ba6a3e01d1da47ecc915e34664ffddaf\"> </a><a name=\"hccomposition-en-ba6a3e01d1da47ecc915e34664ffddaf\"> </a><a name=\"composition-en-ba6a3e01d1da47ecc915e34664ffddaf-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/933/001-002</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - simbrinza</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/14/933/001-002"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mpba6a3e01d1da47ecc915e34664ffddaf"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - simbrinza",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What SIMBRINZA is and what it is used for</li><li>What you need to know before you use SIMBRINZA</li><li>How to use SIMBRINZA</li><li>Possible side effects</li><li>How to store SIMBRINZA</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What simbrinza is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What simbrinza is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SIMBRINZA contains two active substances, brinzolamide and brimonidine tartrate. Brinzolamide belongs to a group of medicines called carbonic anhydrase inhibitors and brimonidine tartrate belongs to a group of medicines called alpha-2 adrenergic receptor agonists. Both substances work together to reduce pressure within the eye.</p><p>SIMBRINZA is used to lower pressure in the eyes in adult patients (aged 18 years and over) who have eye conditions known as glaucoma or ocular hypertension and whose high pressure in the eyes cannot be controlled effectively by one medicine alone.</p></div>"
}
},
{
"title" : "2. What you need to know before you take simbrinza",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take simbrinza"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use SIMBRINZA</p><ul><li>if you are allergic to brinzolamide or brimonidine tartrate or any of the other ingredients of this medicine (listed in section 6)</li><li>if you are allergic to sulphonamides (examples include medicines used to treat diabetes and infections and also diuretics (water tablets))</li><li>if you are taking a monoamine oxidase (MAO) inhibitors (examples include medicines to treat depression or Parkinson s disease) or certain antidepressants. You must inform your doctor if you are taking any antidepressant medicines</li><li>if you have severe kidney problems</li><li>if you have too much acidity in your blood (a condition called hyperchloraemic acidosis)</li><li>in babies and infants aged less than 2 years.</li></ul><p>Warnings and precautions Talk to your doctor, optometrist (optician) or pharmacist before using SIMBRINZA if you have now or have had in the past:</p><ul><li>liver problems</li><li>a type of high pressure in the eyes called narrow-angle glaucoma</li><li>dry eyes or cornea problems</li><li>coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, high or low blood pressure</li><li>depression</li><li>disturbed or poor blood circulation (such as Raynaud s disease, Raynaud s syndrome or cerebral insufficiency).</li><li>if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using SIMBRINZA or other related medicines.</li></ul><p>Take special care with SIMBRINZA: Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in association with brinzolamide treatment. Stop using SIMBRINZA and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4. If you wear soft contact lenses, do not use the drops with your lenses in. See section Wearing contact lenses - SIMBRINZA contains benzalkonium chloride below).</p><p>Children and adolescents SIMBRINZA is not intended for use by children and adolescents aged below 18 years because it has not been studied in this age group. It is particularly important that the medicine is not used in children under the age of 2 years (see section Do not use SIMBRINZA above) because it is unlikely to be safe.</p><p>Other medicines and SIMBRINZA Tell your doctor, optometrist (optician) or pharmacist if you are using, have recently used, or might use any other medicines.</p><p>SIMBRINZA can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.</p><p>Tell your doctor if you are taking or intend to take any of the following medicines:</p><ul><li>medicines to lower blood pressure</li><li>heart medicines including digoxin (used to treat heart conditions)</li><li>other medicines for glaucoma that also treat altitude sickness known as acetazolamide, methazolamide and dorzolamide</li><li>medicines that can affect the metabolism, such as chlorpromazine, methylphenidate and reserpine</li><li>antiviral, antiretroviral (used to treat Human Immunodeficiency Virus (HIV)) or antibiotic medicines</li><li>antiyeast or antifungal medicines</li><li>monoamine oxidase (MAO) inhibitors, or antidepressants including amitriptyline, nortriptyline, clomipramine, mianserin, venlafaxine and duloxetine</li><li>anaesthetics</li><li>sedatives, opiates, or barbiturates</li></ul><p>You should also tell your doctor if the dose of any of your current medicines is changed.</p><p>SIMBRINZA with alcohol If you regularly consume alcohol, ask your doctor, optometrist (optician) or pharmacist for advice before taking this medicine. SIMBRINZA can be affected by alcohol.</p><p>Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, optometrist (optician) or pharmacist for advice before taking this medicine. Women who may become pregnant are advised to use effective contraception during SIMBRINZA treatment. The use of SIMBRINZA is not recommended during pregnancy. Do not use SIMBRINZA unless clearly indicated by your doctor.</p><p>If you are breast-feeding, SIMBRINZA may pass into your milk. The use of SIMBRINZA is not recommended during breast-feeding.</p><p>Driving and using machines You may find that your vision is blurred or abnormal for a time just after using SIMBRINZA. SIMBRINZA may also cause dizziness, drowsiness or tiredness in some patients.</p><p>Do not drive or use machines until the symptoms are cleared.</p><p>Wearing contact lenses - SIMBRINZA contains benzalkonium chloride</p><p>This medicine contains 0.15 mg benzalkonium chloride in each 5 ml, which is equivalent to 0.03 mg/ml.</p><p>Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards. Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or a disorder of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.</p></div>"
}
},
{
"title" : "3. How to take simbrinza",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take simbrinza"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor, optometrist (optician) or pharmacist has told you. Check with your doctor, optometrist (optician) or pharmacist if you are not sure.</p><p>Only use SIMBRINZA for your eyes. Do not swallow or inject.</p><p>The recommended dose is one drop in the affected eye or eyes two times a day. Use at the same time each day.</p><p>How to use</p><p>Wash your hands before you start.</p><p>1 2</p><p>Shake well before use. Twist off the bottle cap. After the cap is removed, if the tamper evident snap collar is loose, remove it before using the medicine. Do not touch the dropper with your fingers when opening or closing the bottle. It could infect the drops. Hold the bottle, pointing down, between your thumb and fingers. Tilt your head back. Pull down your lower eyelid with a clean finger, until there is a pocket between the eyelid and your eye. The drop will go in here (picture 1). Bring the bottle tip close to the eye. Do this in front of a mirror if it helps. Do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. It could infect the drops. Gently press on the base of the bottle to release one drop of SIMBRINZA. Do not squeeze the bottle: it is designed so that a gentle press on the bottom is all that it needs (picture 2).</p><p>To reduce the amount of medicine that could come into the rest of the body after application of the eye drop, close your eye and apply gentle pressure to the corner of the eye next to the nose with a finger for at least 2 minutes.</p><p>If you use drops in both eyes, repeat the steps for your other eye. It is not necessary to close and shake the bottle before you apply the drop in your other eye. Close the bottle cap firmly immediately after use.</p><p>If you are using other eye drops as well as SIMBRINZA, wait at least five minutes between using SIMBRINZA and the other drops.</p><p>If a drop misses your eye, try again.</p><p>If you use more SIMBRINZA than you should Rinse your eye with warm water. Do not put in any more drops until it is time for your next regular dose.</p><p>Adults who accidentally swallowed medicines containing brimonidine experienced a decreased heart rate, decreased blood pressure which may be followed by increased blood pressure, heart failure, difficulty breathing and effects in the nervous system. Should this happen, contact your doctor immediately.</p><p>Serious side effects have been reported in children who accidently swallowed medicines containing brimonidine. Signs included sleepiness, floppiness, low body temperature, paleness and breathing difficulties. Should this happen, contact your doctor immediately.</p><p>If SIMBRINZA has been accidentally swallowed then you should contact your doctor immediately.</p><p>If you forget to use SIMBRINZA Continue with the next dose as planned. Do not use a double dose to make up for a forgotten dose. Do not use more than one drop in the affected eye(s) two times a day.</p><p>If you stop using SIMBRINZA Do not stop using SIMBRINZA without first speaking to your doctor. If you stop using SIMBRINZA the pressure in your eye will not be controlled, which could lead to loss of sight.</p><p>If you have any further questions on the use of this medicine, ask your doctor, optometrist (optician) or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you experience any of the following side effects, please stop using this medicine and seek immediate medical attention as these could be signs of a reaction to the medicine. The frequency of an allergic reaction to the medicine is not known (frequency cannot be estimated from the available data).</p><ul><li>Severe skin reactions, including rash or redness or itching on your body or eyes</li><li>Trouble breathing</li><li>Chest pain, irregular heart beat</li></ul><p>Contact your doctor immediately if you develop extreme tiredness or dizziness.</p><p>The following side effects have been observed with SIMBRINZA and other medicines containing brinzolamide or brimonidine alone.</p><p>Stop using SIMBRINZA and seek medical attention immediately if you notice any of the following symptoms:</p><ul><li>reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>Effects in the eye: allergic conjunctivitis (eye allergy), eye surface inflammation, eye pain, eye discomfort, blurred or abnormal vision, eye redness</li><li>General side effects: drowsiness, dizziness, bad taste in mouth, dry mouth</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Effects in the eye: eye surface damage with loss of cells, inflammation of the eyelid, deposits on the eye surface, sensitivity to light, swelling of the eye (affecting the cornea or eyelid), dry eye, eye discharge, watery eye, eyelid redness, abnormal or decreased sensation in eye, tired eye, reduced vision, double vision, product particles in eyes.</li><li>General side effects: decreased blood pressure, chest pain, irregular heartbeat, slow or fast heart rate, palpitations, difficulty sleeping (insomnia), nightmares, depression, generalised weakness, headache, dizziness, nervousness, irritability, general feeling of being unwell, memory loss, shortness of breath, asthma, nose bleeds, cold symptoms, dry nose or throat, sore throat, throat irritation, cough, runny nose, stuffy nose, sneezing, sinus infection, chest congestion, ringing in ear, indigestion, intestinal gas or stomach ache, nausea, diarrhoea, vomiting, abnormal sensation in mouth, increased allergic symptoms on skin, rash, abnormal skin sensation, hair loss, generalised itching, increased blood chlorine levels, or decreased red blood cell count as seen in a blood test, pain, back pain, muscle pain or spasm, kidney pain such as lower back pain, decreased libido, male sexual difficulty.</li></ul><p>Very rare (may affect up to 1 in 10 000 people)</p><ul><li>Effects in the eye: decreased pupil size</li><li>General side effects: fainting, increased blood pressure</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>Effects in the eye: decreased growth of eyelashes</li><li>General side effects: tremor, decreased sensation, loss of taste, abnormal liver function values as seen in a blood test, swelling of the face, joint pain, frequent urination, chest pain, swelling of the extremities, reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, which can be preceded by fever and flu-like symptoms. These serious skin rashes can be potentially life- threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis). Reporting of side effects If you get any side effects, talk to your doctor, optometrist (optician) or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</li></ul></div>"
}
},
{
"title" : "5. How to store simbrinza",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store simbrinza"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP . The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Throw away the bottle 4 weeks after first opening to prevent infections and use a new bottle. Write down the date of opening on the carton in the space provided.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your optometrist (optician) or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What SIMBRINZA contains</p><ul><li>The active substances are brinzolamide and brimonidine tartrate. One ml of suspension contains 10 mg of brinzolamide and 2 mg of brimonidine tartrate equivalent to 1.3 mg brimonidine.</li><li>The other ingredients are benzalkonium chloride (see section 2 Wearing contact lenses - SIMBRINZA contains benzalkonium chloride ), propylene glycol, carbomer 974P, boric acid, mannitol, sodium chloride, tyloxapol, hydrochloric acid and/or sodium hydroxide and purified water.</li></ul><p>Tiny amounts of hydrochloric acid and/or sodium hydroxide are added to keep acidity levels (pH levels) normal.</p><p>What SIMBRINZA looks like and contents of the pack SIMBRINZA eye drops, suspension, is a liquid (white-to-off-white suspension) supplied in a pack containing one or three 5 ml plastic bottles with screw cap.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland</p><p>Manufacturer Novartis Farmac utica, S.A. Gran Via de les Corts Catalanes, 08013 Barcelona Spain</p><p>S.A. Alcon-Couvreur N.V. Rijksweg BE-2870 Puurs Belgium</p><p>Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany</p><p>Siegfried El Masnou, S.A. Camil Fabra El Masnou 08320 Barcelona Spain</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16<br/>Novartis Bulgaria EOOD .: +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0</p><p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20<br/>Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: + 421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1</p><p>Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133<br/>Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mpba6a3e01d1da47ecc915e34664ffddaf",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mpba6a3e01d1da47ecc915e34664ffddaf",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpba6a3e01d1da47ecc915e34664ffddaf\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpba6a3e01d1da47ecc915e34664ffddaf</b></p><a name=\"mpba6a3e01d1da47ecc915e34664ffddaf\"> </a><a name=\"hcmpba6a3e01d1da47ecc915e34664ffddaf\"> </a><a name=\"mpba6a3e01d1da47ecc915e34664ffddaf-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/933/001-002</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: SIMBRINZA 10 mg/mL + 2 mg/mL eye drops, suspension</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/14/933/001-002"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "SIMBRINZA 10 mg/mL + 2 mg/mL eye drops, suspension",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
